Although AbbVie has lost patent exclusivity for its flagship drug, Humira, the company may soon be bigger and better.

We recently published a list of the 12 Best Stocks to Buy in 2025 for Beginners. In this article, we are going to take a look ...

In last year's update, AbbVie raised the combined 2027 net sales guidance for Skyrizi and Rinvoq by $6 billion to $27 billion ...

Let's decide whether AbbVie is a buy. In the pharmaceutical business ... and $8.7 billion for Cerevel Therapeutics. The company's ratio of debt to EBITDA (earnings before interest, taxes ...

Let's decide whether AbbVie is a buy. In the pharmaceutical business ... and $8.7 billion for Cerevel Therapeutics.

Tom Lee, Fundstrat Global Advisors managing partner and head of research, appeared on CNBC to talk about his 2025 playbook.

Pharmaceutical stocks can bring an element of safety to your portfolio. Why is this the case? These companies make drugs ...